Irbesartan is an angiotensin receptor blocker used to treat hypertension, delay progression of diabetic nephropathy, and treat congestive heart failure. It can also be used as part of a combination product with hydrochlorothiazide for patients not well controlled or not expected to be well controlled on monotherapy.
- Mechanism
- Curator reviewed · 8 references
Irbesartan prevents angiotensin II binding to the AT1 receptor in tissues like vascular smooth muscle and the adrenal gland. Irbesartan and its active metabolite bind the AT1 receptor with 8500 times more affinity than they bind to the AT2 receptor. Irbesartan's prevention of angiotensin II binding causes vascular smooth muscle relaxation and prevents the secretion of aldosterone, lowering blood pressure.
Angiotensin II would otherwise bind to the AT1 receptor, inducing vasoconstriction and aldosterone secretion, raising blood pressure.
- Primary indication
- Irbesartan is indicated to treat hypertension and diabetic nephropathy in hypertensive patients with type 2 diabetes, elevated serum creatinine, and proteinuria.Curator reviewed · 4 structured indications
- Formula / weight
- C25H28N6O · 428.5294 g/mol (avg)
- First approval
- Canada, 2006 · United States, 1997 · European Union, 2016
- Code names
- BMS-186295 · SR-47436
- Brand names
Resolves to
YOSHYTLCDANDAN-UHFFFAOYSA-NSMILESCCCCC1=NC2(CCCC2)C(=O)N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1What you can answer from here — as of September 21, 2026
Which drugs share a target with Irbesartan, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account